



COMMONWEALTH OF MASSACHUSETTS
Office of Consumer Affairs and Business Regulation
DIVISION OF INSURANCE

1000 Washington Street, Suite 810 • Boston, MA 02118-6200
(617) 521-7794 • Toll-free (877) 563-4467
<http://www.mass.gov/doi>

CHARLES D. BAKER
GOVERNOR

KARYN E. POLITO
LIEUTENANT GOVERNOR

MIKE KENNEALY
SECRETARY OF HOUSING AND
ECONOMIC DEVELOPMENT

EDWARD A. PALLESCHI
UNDERSECRETARY OF CONSUMER AFFAIRS
AND BUSINESS REGULATION

GARY D. ANDERSON
COMMISSIONER OF INSURANCE

BULLETIN 2019-07

To: Commercial Health Insurers, Blue Cross and Blue Shield of Massachusetts, Inc.,
and Health Maintenance Organizations

From: Gary D. Anderson, Commissioner of Insurance

Date: August 29, 2019

Re: Common Procedure Coding Systems for Opioid Agonist and Antagonist Treatments

The Division of Insurance (“Division”) issues this bulletin to Commercial Health Insurers, Blue Cross and Blue Shield of Massachusetts, Inc., and Health Maintenance Organizations offering insured health benefit plans in Massachusetts and behavioral health management firms and third party administrators under contract to these companies (collectively, “Carriers”).

This bulletin provides guidance to contracting providers who are initiating or continuing opioid agonist and antagonist treatments regarding common procedure coding to be used when submitting claims for those agonist or antagonist treatments pursuant to the provisions of Section 106 of Chapter 208 of the Acts of 2018.

The guidance applies to opioid agonist or antagonist treatment when provided within the following provider settings: (i) acute care hospital emergency departments or satellite emergency facilities; (ii) community-based treatment facilities, outpatient clinics, primary care practices, opioid treatment programs, or office-based treatment clinics; (iii) inpatient facilities providing treatment for substance use disorders; and (iv) any facility used for commitment pursuant to section 35 of chapter 123 of the General Laws for persons with a substance use disorder (collectively, “Providers”).

Opioid Agonist Treatments

Carriers are instructed to establish appropriate systems that will allow for opioid agonist treatments to be available when medically necessary and appropriate to persons covered under insured benefit plans. For the purposes of this bulletin, the Division uses the following definitions:

- Opioid agonist treatment: refers to medications approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder by binding and fully activating the mu-opioid receptor, thereby lessening the symptoms of withdrawal. At adequate doses,

these medications establish opioid blockade and reduce or eliminate cravings for other opioids. Opioid agonist treatment includes the generic medication methadone.

- Partial opioid agonist treatment: refers to medications approved by the FDA to treat opioid use disorder by binding yet only partially activating the mu-opioid receptor, thereby lessening the symptoms of withdrawal. At adequate doses, these medications establish opioid blockade, and reduce or eliminate cravings for other opioids. Partial opioid agonist treatment includes the generic medications buprenorphine and buprenorphine/naloxone.
- Medication-assisted treatment: refers to the Substance Abuse and Mental Health Services Administration (SAMHSA) definition, which is “the use of FDA-approved medications, in combination with counseling and behavioral therapies, to provide a ‘whole-patient’ approach to the treatment of substance use disorders.” Although this bulletin is specifically focused on the pharmacological components of medication-assisted treatment (“Medications for Addiction Treatment” or “MAT”), the Division recognizes that a patient may require diagnostic, medical, and behavioral services in addition to MAT in order to address the patient’s full complement of needs.

Carriers’ systems are expected to provide medically necessary access to at least one (1) opioid agonist treatment and at least one (1) partial agonist treatment without preauthorization up to the FDA-approved dose recommendations, but not exceeding FDA daily dose limitations, for treatment of opioid use disorder. Any amount beyond FDA-approved recommendations may be subject to a carrier’s preauthorization requirements. Carriers may administer opioid agonist and partial agonist treatments as either prescription drug or medical benefits, but treatments that are treated as medical benefits must be at least as generous as such benefits would be if treated as a prescription benefit.

Carriers may limit coverage of opioid agonist and partial agonist treatments to those prescription drugs on their formularies or to generic types of drugs, provided that Carriers institute appropriate exception procedures where brand-name or off-formulary prescription drugs are medically indicated for the patient. Carriers with managed care networks are expected to establish networks with adequate access to opioid agonist treatment and partial agonist treatment for all covered persons within the Carrier’s service delivery system.

The Division would find it appropriate if Carriers’ systems enable access to at least buprenorphine monotherapy or buprenorphine/naloxone combination therapy, for doses of up to 16 milligrams per day, to be covered without preauthorization so that clinicians can make decisions based on the patient profile and whether the medication is being given under supervision or is being given as a take-home dosing kit. For doses greater than 16mg/day, carriers may institute authorizations for continued use to ensure patients are maintained on the lowest possible dose. Additionally, carriers must not impose any policies pertaining to take-home medications, including methadone, that are more restrictive than those set forth in 105 CMR 164.00. Medications for Addiction Treatment can be provided in a variety of healthcare settings by a range of practitioners, including but not limited to (i) acute care hospital emergency departments or satellite emergency facilities; (ii) community-based treatment facilities, outpatient clinics, primary care practices, opioid treatment programs, or office-based treatment clinics; (iii) inpatient facilities providing treatment for substance use disorders; and (iv) any facility used for commitment pursuant to section 35 of chapter 123 of the General Laws for persons with a substance use disorder.

Opioid Antagonist Treatments

In addition, opioid antagonist treatments are available. Naltrexone is available without prior authorization and without a specialty pharmacy requirement for at least the first fill. For naloxone, plans are required to cover at least one formulation of naloxone without prior authorization in accordance with guidance as issued by the Division. Furthermore, the Department of Public Health issued a statewide standing order pursuant to Section 32 of Chapter 208 of the Acts of 2018 for the broad distribution of naloxone to any resident of the Commonwealth.

Common Coding Systems for Opioid Agonist and Antagonist Treatments

The Division acknowledges the benefits of developing a set of common codes that apply to opioid agonist and antagonist treatments to facilitate Providers' billing of covered services. The Division recognizes that methods and rates of reimbursement are negotiated between Carriers and Providers; thus, no one method perfectly serves in all situations, especially where Carriers and Providers may bundle services into one common payment code.

The Division therefore establishes a set of claim codes that are representative of services specific to opioid agonist and antagonist treatments that could be used by Carriers and Providers when negotiating the appropriate way to develop methods and rates of reimbursement for covered members. The codes, which are identified in Appendices 1 and 2, represent a baseline set of codes that may be used as Carriers and Providers negotiate contracts.

As to the codes and payment policies utilized by an individual Carrier's health plan, network providers will need to refer to provisions included within their contracts with their payer.

Coding for Other Services Provided During Opioid Agonist or Antagonist Treatments

While an individual is undergoing opioid agonist or antagonist treatments or partial opioid agonist treatment, a Provider may identify other services that the Provider believes the individual may need to test or be treated for, including, for example, testing for hepatitis or other conditions. These services are subject to medical necessity review and may be subject to the Carrier's prior authorization, utilization review, and/or payment policy protocols.

Under M.G.L. c. 176O, insured health plans may develop medical necessity criteria to determine whether certain services are medically necessary and appropriate to treat a person's condition. As noted in M.G.L. c. 176O, §16(b):

A carrier may develop guidelines to be used in applying the standard of medical necessity, as defined in this subsection. Any such medical necessity guidelines utilized by a carrier in making coverage determinations shall be: (i) developed with input from practicing physicians and participating providers in the carrier's or utilization review organization's service area; (ii) developed under the standards adopted by national accreditation organizations; (iii) updated at least biennially or more often as new treatments, applications and technologies are adopted as generally accepted professional medical practice; and (iv) evidence-based, if practicable. In applying such guidelines, a carrier shall consider the individual health care needs of the insured.

Any such medical necessity guidelines criteria shall be applied consistently by a carrier or a utilization review organization and made easily accessible and up-to-date on a carrier or utilization review organization's website to subscribers, health care providers and the general public. If a carrier or utilization review organization

intends either to implement a new medical necessity guideline or amend an existing requirement or restriction, the carrier or utilization review organization shall ensure that the new or amended requirement or restriction shall not be implemented unless the carrier's or utilization review organization's website has been updated to reflect the new or amended requirement or restriction.

When processing a claim for any of such services, a Provider should follow the appropriate procedural coding systems identified by the member's Carrier.

If you have any questions about this bulletin, please contact Kevin Beagan, Division of Insurance, at (617) 521-7323 or kevin.beagan@mass.gov.

Appendix 1

Coding used for addiction treatment when administered by a clinician, orally or through injection, based on National Drug Coding (NDC) and Procedure Codes Identified as Medications for Addiction Treatment

HCPCS codes for MAT:

H0020	Methadone dose and administration
J0571	Buprenorphine, oral, 1 mg
J0572	Buprenorphine/ Naloxone, oral, less than or equal to 3 mg buprenorphine
J0573	Buprenorphine/ Naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
J0574	Buprenorphine/ Naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
J0575	Buprenorphine/ Naloxone, oral, greater than 10 mg buprenorphine
S0109	Methadone, oral, 5 mg
J1230	Injection, Methadone HCL, up to 10mg
J2315	Injection, Naltrexone, up to 1mg

NDCs for Buprenorphine:

00054017613	Buprenorphine Hydrochloride
00054017713	Buprenorphine Hydrochloride
00054018813	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00054018913	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00093537856	Buprenorphine Hydrochloride
00093537956	Buprenorphine Hydrochloride
00093572056	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00093572156	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00228315303	Buprenorphine Hydrochloride
00228315403	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00228315473	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00228315503	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00228315573	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00228315603	Buprenorphine Hydrochloride
00378092393	Buprenorphine Hydrochloride
00378092493	Buprenorphine Hydrochloride
00406192303	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00406192403	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00490005100	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00490005130	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00490005160	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
00490005190	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496120201	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496120203	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496120401	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496120403	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496120801	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496120803	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496121201	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496121203	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496127802	Buprenorphine Hydrochloride
12496128302	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496130602	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
12496131002	Buprenorphine Hydrochloride
16590066605	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
16590066630	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
16590066705	Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate

16590066730 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
16590066790 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
23490927003 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
23490927006 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
23490927009 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
35356000407 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
35356000430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
35356055530 Buprenorphine Hydrochloride
35356055630 Buprenorphine Hydrochloride
42291017430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
42291017530 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
43063018407 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
43063018430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
49999039507 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
49999039515 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
49999039530 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
52959030430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
52959074930 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
53217013830 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123011430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123091430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123092930 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123095730 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123098630 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569573900 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569573901 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569573902 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569639900 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569640800 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569657800 Buprenorphine Hydrochloride
54868570700 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570701 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570702 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570703 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570704 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868575000 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55045378403 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55700014730 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55700018430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55700030230 Buprenorphine Hydrochloride
55700030330 Buprenorphine Hydrochloride
59385001201 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001230 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001401 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001601 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001630 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629402801 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629403401 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629403402 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629403403 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629409201 Buprenorphine Hydrochloride
63874108403 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63874108503 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63874117303 Buprenorphine Hydrochloride

65162041503 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
65162041603 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
66336001630 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68071138003 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68071151003 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68258299103 Buprenorphine Hydrochloride
68258299903 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68308020230 Buprenorphine Hydrochloride
68308020830 Buprenorphine Hydrochloride
52959030430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
52959074930 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
53217013830 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123011430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123091430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123092930 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123095730 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54123098630 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569573900 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569573901 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569573902 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569639900 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569640800 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54569657800 Buprenorphine Hydrochloride
54868570700 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570701 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570702 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570703 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868570704 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
54868575000 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55045378403 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55700014730 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55700018430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
55700030230 Buprenorphine Hydrochloride
55700030330 Buprenorphine Hydrochloride
59385001201 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001230 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001401 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001430 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001601 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
59385001630 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629402801 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629403401 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629403402 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629403403 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63629409201 Buprenorphine Hydrochloride
63874108403 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63874108503 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
63874117303 Buprenorphine Hydrochloride
65162041503 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
65162041603 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
66336001630 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68071138003 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68071151003 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate
68258299103 Buprenorphine Hydrochloride
68258299903 Buprenorphine Hydrochloride / Naloxone Hydrochloride Dihydrate

68308020230 Buprenorphine Hydrochloride

68308020830 Buprenorphine Hydrochloride

NDCs for Naltrexone

00056001122 Naltrexone HCL
00056001130 Naltrexone HCL
00056001170 Naltrexone HCL
00056007950 Naltrexone HCL
00056008050 Naltrexone HCL
00185003901 Naltrexone HCL
00185003930 Naltrexone HCL
00406009201 Naltrexone HCL
00406009203 Naltrexone HCL
00406117001 Naltrexone HCL
00406117003 Naltrexone HCL
00555090201 Naltrexone HCL
00555090202 Naltrexone HCL
16729008101 Naltrexone HCL
16729008110 Naltrexone HCL
42291063230 Naltrexone HCL
43063059115 Naltrexone HCL
47335032683 Naltrexone HCL
47335032688 Naltrexone HCL
50436010501 Naltrexone HCL
51224020630 Naltrexone HCL
51224020650 Naltrexone HCL
51285027501 Naltrexone HCL
51285027502 Naltrexone HCL
52152010502 Naltrexone HCL
52152010504 Naltrexone HCL
52152010530 Naltrexone HCL
54868557400 Naltrexone HCL
63459030042 Naltrexone Microspheres
65694010003 Naltrexone HCL
65694010010 Naltrexone HCL
65757030001 Naltrexone Microspheres
65757030202 Naltrexone Microspheres
68084029111 Naltrexone HCL
68084029121 Naltrexone HCL
68094085362 Naltrexone HCL
68115068030 Naltrexone HCL

Source: Center for Medicare and Medicaid Services (CMS) Chronic Conditions Data Warehouse (CCW) – Opioid-related indicators and Algorithms. 2018. <https://www.ccwdata.org/web/guest/condition-categories>

Appendix 2

Coding used by for assessment, evaluation, prescribing, and administration of medications for addiction treatment

CPT 99201-99205	Outpatient visit for the evaluation and management of a new patient
CPT 99211-99215	Office or other outpatient visit for the evaluation and management of an established patient
CPT 99281-99285	Initial/normal ED charges
CPT 96372	Therapeutic prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
CPT 99217-99220	Initial Observation (New or Established Patient)
HCPCS H0001	Alcohol and/or drug assessment (substance use disorder programs only)
HCPCS H0020	Alcohol and/or drug services methadone administration and/or service (provision of the drug by a licensed program) (dose only visit) (substance use disorder programs only)
HCPCS H0033	Oral medication administration, direct observation (substance use disorder programs only)
HCPCS T1015	Clinic visit/encounter, all-inclusive (community health centers only)
CPT 99199	Other Medicine Services and Procedures (Tracking and monitoring of Naloxone dispensing at discharge)

Carriers should refer Providers to their plan contracts for carrier-specific coding information.